Topic Archives: CRISPR Therapeutics (CRSP)

“This Wednesday, September 5 Tuesday, May 28, a group of scientists will take the stage at a prestigious medical conference… “And announce to the world the potential end of disease as we know it.” That’s the attention-getting part of Ray Blanco’s latest teaser ad for his FDA Trader newsletter that Gumshoe readers have been asking […]

Here’s a bit from the email that Matt McCall sent out introducing his lastest teaser ad: “When it comes down to it, there are really just three ways to get truly rich in the stock market. You can put thousands into the market every year, hold for decades, and retire with a fortune. You can […]

The article below was originally published on November 27, 2017, when Jeff Brown’s ads promoting the “God Key” started to show up in our inboxes. It has not been updated or revised, but the new versions of the ad from Brown are very similar to the ones we covered in November, including the description of […]

Fear Of Missing Out is such a big deal that it gets its own acronym in my book (FOMO — and a clever FOMO-fueling website here), and it drives investors to take huge chances just so they don’t have to worry about missing a chance at stupendous gains. That’s what many newsletter ads use to […]

Comments

  • Travis Johnson, Stock Gumshoe

    We keep seeing this ad and getting more questions about it -- the ad hasn't changed in any big way that I've noticed, th...

  • Avatar

    I've often wondered how companies that develop something that eliminates disease, such as this, will make money. The OUT...

  • Avatar

    $12 trillion? That's over half of the US economy. Even over 10 years, it's never going to happen. I guess for $79/yea...

  • Avatar

    Well I just hope this is a boomer like the "God Key" stocks (EDIT, CRSP) which are about 50% lower from their peaks in 2...

  • Avatar

    Although the last three months is a short time period, it's the only one I could research easily. Over that period, the...

  • Avatar

    I think its cell data. https://www.investors.com/news/technology/crispr-gene-editing-biotech-companies/ https://mo...

  • Avatar

    There've been a lot of uncertainties around the CRISPR companies, but I think right now the elephant in the room is the ...

  • Avatar

    Found the article I remember that talks about the patent license. https://www.forbes.com/sites/matthewherper/2015/08/10/...

  • Avatar

    Amazing how they can predict uranium demand (prices) over the next 15 years or more. After you've spent about $75,000-$...

  • Avatar

    Thanks for putting everything into perspective. I read about "exciting new developments" every day, and it is impossibl...

  • Avatar

    I bought CRSP and I am up over 60%. Might think about the other two as well. This technology will take some time to deve...

  • Avatar

    I gave up on EDIT, NTLA, and CRSP and went with Illumina, Inc. (ILMN) which is similar but much less volatile. And ILMN ...

  • Avatar

    If you read all the way down to the end of Altucher's epic screed you see that he says you should buy all three: EDIT, N...

  • Travis Johnson, Stock Gumshoe

    I have a really hard time with R&D companies or very early-stage clinical biotechs -- partly because it's an end market ...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch